Merus Stock Forecast, Price & News

-0.51 (-2.16 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume94,188 shs
Average Volume191,000 shs
Market Capitalization$887.42 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

Merus logo

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.05 out of 5 stars

Medical Sector

65th out of 2,099 stocks

Pharmaceutical Preparations Industry

26th out of 830 stocks

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Merus (NASDAQ:MRUS) Frequently Asked Questions

Is Merus a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Merus stock.
View analyst ratings for Merus
or view top-rated stocks.

What stocks does MarketBeat like better than Merus?

Wall Street analysts have given Merus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Merus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Merus?

Merus saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,320,000 shares, an increase of 41.7% from the May 13th total of 931,400 shares. Based on an average daily volume of 190,000 shares, the days-to-cover ratio is currently 6.9 days. Currently, 4.5% of the shares of the stock are sold short.
View Merus' Short Interest

When is Merus' next earnings date?

Merus is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Merus

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) released its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.08. Merus had a negative trailing twelve-month return on equity of 57.90% and a negative net margin of 248.38%.
View Merus' earnings history

How has Merus' stock been impacted by Coronavirus?

Merus' stock was trading at $14.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRUS stock has increased by 59.1% and is now trading at $23.14.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MRUS?

6 equities research analysts have issued twelve-month price targets for Merus' stock. Their forecasts range from $21.00 to $33.00. On average, they expect Merus' share price to reach $29.40 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price.
View analysts' price targets for Merus
or view top-rated stocks among Wall Street analysts.

Who are Merus' key executives?

Merus' management team includes the following people:
  • Dr. Sven Ante Lundberg, CEO, Pres, Principal Financial Officer & Exec. Director (Age 58, Pay $33.24k)
  • Mr. Hui Liu, Chief Bus. Officer, Exec. VP & Head of Merus U.S. (Age 54, Pay $546.03k)
  • Dr. Hennie Hoogenboom, Co-Founder and Scientific Advisor
  • Mr. Cornelis Adriaan de Kruif Ph.D., CTO & Sr. VP (Age 57)
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. Peter B. Silverman J.D., Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal (Age 43)
  • Mr. Alexander Berthold Hendrik Bakker Ph.D., Chief Devel. Officer & Sr. VP (Age 54)
  • Dr. Andrew Joe M.D., Chief Medical Officer (Age 55)
  • Ms. Anne Van der Touw Noordzij, Company Sec.
  • Harry Shuman, VP & Controller

Who are some of Merus' key competitors?

What other stocks do shareholders of Merus own?

When did Merus IPO?

(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Who are Merus' major shareholders?

Merus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (19.00%), Federated Hermes Inc. (8.04%), Boxer Capital LLC (4.95%), Morgan Stanley (1.27%), Silverarc Capital Management LLC (0.64%) and Platinum Investment Management Ltd. (0.56%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology.
View institutional ownership trends for Merus

Which institutional investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Ikarian Capital LLC, Platinum Investment Management Ltd., and Northern Trust Corp.
View insider buying and selling activity for Merus
or view top insider-selling stocks.

Which institutional investors are buying Merus stock?

MRUS stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Boxer Capital LLC, Silverarc Capital Management LLC, Morgan Stanley, Octagon Capital Advisors LP, Franklin Resources Inc., Perceptive Advisors LLC, and Vivo Capital LLC. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Merus
or or view top insider-buying stocks.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $23.14.

How much money does Merus make?

Merus has a market capitalization of $887.42 million and generates $29.94 million in revenue each year. The biotechnology company earns $-85,510,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How many employees does Merus have?

Merus employs 93 workers across the globe.

What is Merus' official website?

The official website for Merus is

Where are Merus' headquarters?

Merus is headquartered at YALELAAN 62, UTRECHT P7, 3584 CM.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.